The utilization of the multimodal immunotherapy for the opsoclonus–myoclonus syndrome can reduce relapses and permanent neurological sequelae
The combination of the intravenous dexamethasone plus IVIG plus rituximab for the OMS can reduce relapses and permanent neurological sequelae.
Authors
- Miriam Kessi (ORCID: https://orcid.org/0000-0002-7932-9292)
- Jing Peng (ORCID: https://orcid.org/0000-0002-7752-6962)
- Ciliu Zhang (ORCID: https://orcid.org/0000-0002-2230-9047)
- Fei Yin (ORCID: https://orcid.org/0000-0002-7192-6308)
- Lifen Yang (ORCID: https://orcid.org/0000-0003-2400-9539)
- Fang He (ORCID: https://orcid.org/0000-0002-7627-0424)
Institutions
- Central South University (CN)
- Education Department of Hunan Province (CN)
- Xiangya Hospital Central South University (CN)
Publication Details
- Journal
- The Italian Journal of Pediatrics/Italian journal of pediatrics
- Published
- 2025-02-07
- DOI
- https://doi.org/10.1186/s13052-025-01875-2
- Primary Topic
- Autoimmune Neurological Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province